Over the past few decades, numerous small molecules have been designed to specifically and selectively target the unusual secondary structure in DNA called the G-quadruplex. Because these ligands have been shown to selectively inhibit the growth of cancer cells, they have become a central focus for the development of novel anticancer agents.